Kuendgen, A., Lauseker, M., List, A. F., Fenaux, P., Giagounidis, A. A., Brandenburg, N. A., . . . Germing, U. (2013). Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): A comparative analysis. Nature Publishing Group.
Citação norma ChicagoKuendgen, A., et al. Lenalidomide Does Not Increase AML Progression Risk in RBC Transfusion-dependent Patients With Low- or Intermediate-1-risk MDS With Del(5q): A Comparative Analysis. Nature Publishing Group, 2013.
Citação norma MLAKuendgen, A., et al. Lenalidomide Does Not Increase AML Progression Risk in RBC Transfusion-dependent Patients With Low- or Intermediate-1-risk MDS With Del(5q): A Comparative Analysis. Nature Publishing Group, 2013.